Today: 14 April 2026
Subscribe
Browse Category

NASDAQ:RGNX 27 June 2025 - 9 March 2026

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics shares jumped 18% Monday after reports that FDA biologics chief Vinay Prasad will depart in April. The move follows the agency’s January rejection of Atara’s EBVALLO therapy for a rare blood cancer, which wiped out 56% of the stock’s value. Atara and partner Pierre Fabre have requested a Type A meeting with the FDA to revisit the decision. Atara ended 2025 with $8.5 million in cash.
9 March 2026
····
Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics shares rose 3.7% to $21.62 Thursday after the FDA halted Regenxbio’s gene therapy trials over a brain tumor case, intensifying focus on Denali’s Hunter syndrome drug under FDA review. Investors await Denali’s clinical data update in early February and a regulatory decision by April 5. The iShares Nasdaq Biotechnology ETF was little changed.
29 January 2026
····
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

The FDA approved Abeona’s Zevaskyn, the first cell-based gene therapy for RDEB, in April 2025, with launch set for Q3 at $3.1 million. Vertex’s CRISPR therapy Casgevy generated $2 million in Q3 2024. Novo Holdings acquired Catalent for $16.5 billion in January 2025 to secure GLP-1 drug manufacturing. Johnson & Johnson bought Intra-Cellular Therapies for $14.6 billion, expanding its neuroscience portfolio.
27 June 2025
···········

Stock Market Today

  • News Corp Launches US$1 Billion Nasdaq Share Buy-Back Program
    April 13, 2026, 10:44 PM EDT. News Corporation has updated its share repurchase plan, authorizing up to US$1 billion in buy-backs exclusively of its Nasdaq-listed Class A and Class B common stock. The program excludes ASX-listed Chess Depositary Interests (CDIs), focusing on the U.S. market where liquidity is higher. This move signals the company's intent to manage capital actively and shows potential confidence in its stock valuation. Buy-backs will proceed in the open market or other methods, depending on market conditions and stock price. News Corp's stock currently holds a Buy rating with a A$53 price target, emphasizing positive analyst sentiment. The firm's dual listing strategy supports diverse investor access, with a current market capitalization around A$20.24 billion.

Latest article

Marvell Stock Hits Record High After Nvidia’s $2 Billion Move and Amazon AI Chip Push

Marvell Stock Hits Record High After Nvidia’s $2 Billion Move and Amazon AI Chip Push

13 April 2026
Marvell Technology shares rose 2.1% to $131.22 Monday, hitting a record after Nvidia’s $2 billion investment and renewed optimism over Amazon’s AI chip business. The stock earlier touched $135.18. Barclays upgraded Marvell and raised its price target to $150, citing surging demand for optical products in AI data centers. Nvidia and Marvell plan to link custom chips for Nvidia’s NVLink Fusion platform.
Intel Stock Rally Extends as $100 Billion April Run Draws Fresh Wall Street Bets

Intel Stock Rally Extends as $100 Billion April Run Draws Fresh Wall Street Bets

13 April 2026
Intel shares climbed $2.09 to $64.47 by late morning Monday, extending a rally that has added over $100 billion in value across eight sessions. The surge follows a raised price target, new deals with Google and Elon Musk’s Terafab, and Intel’s $14.2 billion buyback of Apollo’s Fab 34 stake. The stock is up 69% in 2026 after an 84% gain last year. Intel reports first-quarter results April 23.
Nebius Stock (NBIS) Jumps as BofA Backs AI Trade, but Downgrade Flags Valuation Risk

Nebius Stock (NBIS) Jumps as BofA Backs AI Trade, but Downgrade Flags Valuation Risk

13 April 2026
Nebius Group shares climbed 7.4% to $155.74 by midday Monday after Bank of America raised its price target to $175, despite Freedom Capital Markets downgrading the stock to Hold. The Amsterdam-based AI infrastructure firm recently secured a five-year deal with Meta worth up to $27 billion and holds over $40 billion in supply contracts with Microsoft and Meta. Nebius also closed $4.34 billion in convertible debt and sold $2 billion in warrants to Nvidia.
Salesforce Stock News: Choreo and Sumitomo Mitsui Cuts Resurface, but the Filings Are Months Old

Salesforce Stock News: Choreo and Sumitomo Mitsui Cuts Resurface, but the Filings Are Months Old

13 April 2026
Salesforce faced renewed attention after reports of stake reductions by Choreo LLC and Sumitomo Mitsui Trust Group, based on SEC filings from January that reflected year-end positions. Choreo held 27,733 shares and Sumitomo Mitsui 2,478,864 shares as of December 31. The reported cuts amounted to about 35% and 8.6%, respectively. Salesforce shares rose 3.4% Monday, while broader software stocks remain down for the year.
Go toTop